CD News | American Association for Cancer Research
This week: Tidbits from the American Association for Cancer Research (AACR) Annual Meeting, held April 5–10, in San Diego, CA, and other news. Soon, there may be a new standard of care for patients with previously treated KRAS G12C -mutated colorectal cancer, researchers announced at the AACR meeting. The phase I/II KRYSTAL-1 trial, which was concurrently published, tested the KRAS G12C inhibitor adagrasib (Krazati; Mirati) plus the EGFR inhibitor cetuximab (Erbitux) in 94 patients with metastatic